Marshall Edwards Inc.
140 Wicks Road
North Ryde,
NSW 2113
Australia - Map
Phone: 61 2 8877 6196
Fax: 61 2 9878 8474
Web Site: http://www.marshalledwardsinc.com
| Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol. The company was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Christopher Naughton BEc, LLB, 56
Chief Exec. Officer, Pres, Director and Managing Director of Novogen |
$
21.00K | N/A | Mr. David Ross Seaton B Bus KCAE, M Com UNSW, CPA, 54
Chief Financial Officer, Principal Accounting Officer, Company Sec. and Chief Financial Officer of Novogen Limited |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-03
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
